Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.

James H. O'Keefe, Becky K. Captain, Philip G. Jones, William Harris

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25%, LDL-cholesterol by 27%, and the three LDL subfractions by 23%-28% (p

Original languageEnglish (US)
Pages (from-to)154-160
Number of pages7
JournalPreventive Cardiology
Volume7
Issue number4
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

LDL Lipoproteins
Lipoproteins
Dyslipidemias
Lipids
LDL Cholesterol
Hypercholesterolemia
Cross-Over Studies
Atherosclerosis
Placebos
Atorvastatin Calcium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. / O'Keefe, James H.; Captain, Becky K.; Jones, Philip G.; Harris, William.

In: Preventive Cardiology, Vol. 7, No. 4, 09.2004, p. 154-160.

Research output: Contribution to journalArticle

O'Keefe, James H. ; Captain, Becky K. ; Jones, Philip G. ; Harris, William. / Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. In: Preventive Cardiology. 2004 ; Vol. 7, No. 4. pp. 154-160.
@article{36d4f56fb2984973a6e58ac44a6c4b46,
title = "Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.",
abstract = "Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25{\%}, LDL-cholesterol by 27{\%}, and the three LDL subfractions by 23{\%}-28{\%} (p",
author = "O'Keefe, {James H.} and Captain, {Becky K.} and Jones, {Philip G.} and William Harris",
year = "2004",
month = "9",
language = "English (US)",
volume = "7",
pages = "154--160",
journal = "Preventive Cardiology",
issn = "1520-037X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.

AU - O'Keefe, James H.

AU - Captain, Becky K.

AU - Jones, Philip G.

AU - Harris, William

PY - 2004/9

Y1 - 2004/9

N2 - Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25%, LDL-cholesterol by 27%, and the three LDL subfractions by 23%-28% (p

AB - Elevated plasma levels of remnant lipoproteins and small, dense low-density lipoprotein (LDL) particles increase the risk of atherosclerosis. This prospective, placebo-controlled, crossover trial evaluated the effect of atorvastatin on various lipid parameters including remnant lipoproteins and small, dense-LDL cholesterol levels. Forty-five subjects were enrolled in the study. These subjects fell into three distinct lipid patterns: atherogenic dyslipidemia, isolated hypercholesterolemia, and mixed dyslipidemia. Regardless of the baseline lipid profile, atorvastatin (10 mg q x d) reduced levels of remnant lipoproteins by 25%, LDL-cholesterol by 27%, and the three LDL subfractions by 23%-28% (p

UR - http://www.scopus.com/inward/record.url?scp=16544369296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544369296&partnerID=8YFLogxK

M3 - Article

C2 - 15539961

AN - SCOPUS:16544369296

VL - 7

SP - 154

EP - 160

JO - Preventive Cardiology

JF - Preventive Cardiology

SN - 1520-037X

IS - 4

ER -